298 related articles for article (PubMed ID: 32861288)
1. Blastoid Mantle Cell Lymphoma.
Jain P; Wang M
Hematol Oncol Clin North Am; 2020 Oct; 34(5):941-956. PubMed ID: 32861288
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
Zhao S; Kanagal-Shamanna R; Navsaria L; Ok CY; Zhang S; Nomie K; Han G; Hao D; Hill HA; Jiang C; Yao Y; Nastoupil L; Westin J; Fayad L; Nair R; Steiner R; Ahmed S; Samaniego F; Iyer SP; Oriabure O; Chen W; Song X; Zhang J; Badillo M; Moghrabi O; Aranda J; Tang G; Yin CC; Patel K; Medeiros LJ; Li S; Vega F; Thirumurthi S; Xu G; Neelapu S; Flowers CR; Romaguera J; Fowler N; Wang L; Wang ML; Jain P
Am J Hematol; 2020 Jun; 95(6):623-629. PubMed ID: 32239765
[TBL] [Abstract][Full Text] [Related]
3. Sequencing of Novel Therapies for Mantle Cell Lymphoma.
Romancik JT; Cohen JB
Curr Treat Options Oncol; 2021 Nov; 22(12):118. PubMed ID: 34812968
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse.
Oh TS; Burkart M; Behdad A; Savas H; Karmali R
Case Rep Hematol; 2022; 2022():1930546. PubMed ID: 35571529
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic features and management of blastoid variant of mantle cell lymphoma.
Shrestha R; Bhatt VR; Guru Murthy GS; Armitage JO
Leuk Lymphoma; 2015; 56(10):2759-67. PubMed ID: 25747972
[TBL] [Abstract][Full Text] [Related]
6. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management.
Jain P; Wang M
Am J Hematol; 2019 Jun; 94(6):710-725. PubMed ID: 30963600
[TBL] [Abstract][Full Text] [Related]
7. CD5-negative blastoid variant mantle cell lymphoma: a diagnostic dilemma.
Yamamoto N; Maeshima AM; Taniguchi H; Makita S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K
Hum Pathol; 2021 May; 111():84-91. PubMed ID: 33727166
[TBL] [Abstract][Full Text] [Related]
8. A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.
Sawalha Y; Goyal S; Switchenko JM; Romancik JT; Kamdar M; Greenwell IB; Hess BT; Isaac KM; Portell CA; Mejia Garcia A; Goldsmith S; Grover NS; Riedell PA; Karmali R; Burkart M; Buege M; Akhtar O; Torka P; Kumar A; Hill BT; Kahl BS; Cohen JB
Blood Adv; 2023 Jul; 7(13):2983-2993. PubMed ID: 36809796
[TBL] [Abstract][Full Text] [Related]
9. Ki-67 Labeling Indices in 'Classic' versus 'Blastoid' Mantle Cell Lymphomas--Proposed Cutoff Values for Routine Diagnostic Workup.
Pervez S; Haroon S; Awan D
Asian Pac J Cancer Prev; 2015; 16(15):6591-4. PubMed ID: 26434879
[TBL] [Abstract][Full Text] [Related]
10. Hyperleukocytosis increases risk of fatal hyperkalemia with new ibrutinib/venetoclax regimen for refractory mantle cell lymphoma.
Verma A; Mbughuni M; Mariash E; Mesa H
J Chemother; 2019; 31(7-8):428-431. PubMed ID: 31738653
[No Abstract] [Full Text] [Related]
11. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Wang M; Ramchandren R; Chen R; Karlin L; Chong G; Jurczak W; Wu KL; Bishton M; Collins GP; Eliadis P; Peyrade F; Lee Y; Eckert K; Neuenburg JK; Tam CS
J Hematol Oncol; 2021 Oct; 14(1):179. PubMed ID: 34717692
[TBL] [Abstract][Full Text] [Related]
12. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Wang M; Munoz J; Goy A; Locke FL; Jacobson CA; Hill BT; Timmerman JM; Holmes H; Jaglowski S; Flinn IW; McSweeney PA; Miklos DB; Pagel JM; Kersten MJ; Bouabdallah K; Khanal R; Topp MS; Houot R; Beitinjaneh A; Peng W; Fang X; Shen RR; Siddiqi R; Kloos I; Reagan PM
J Clin Oncol; 2023 Jan; 41(3):555-567. PubMed ID: 35658525
[TBL] [Abstract][Full Text] [Related]
13. [Ibrutinib therapy for a blastoid variant mantle cell lymphoma patient with early extranodal relapse after autologous stem cell transplantation].
Nakamura K; Saburi M; Kondo Y; Soga Y; Itani K; Kohno K; Otsuka M; Nakayama T
Rinsho Ketsueki; 2019; 60(12):1663-1668. PubMed ID: 31902818
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States.
Simons CL; Malone D; Wang M; Maglinte GA; Inocencio T; Wade SW; Bennison C; Shah B
J Med Econ; 2021; 24(1):421-431. PubMed ID: 33634729
[TBL] [Abstract][Full Text] [Related]
15. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.
Jain P; Zhang S; Kanagal-Shamanna R; Ok CY; Nomie K; Gonzalez GN; Gonzalez-Pagan O; Hill HA; Lee HJ; Fayad L; Westin J; Nastoupil L; Hagemeister F; Chen W; Oriabure O; Badillo M; Jiang C; Yixin Y; Li S; Tang G; Yin CC; Patel KP; Medeiros LJ; Nair R; Ahmed S; Iyer SP; Thirumurthi S; Champlin R; Xu G; Tinsu P; Santos D; Wang R; Han G; Zhang J; Song X; Neelapu S; Romaguera J; Futreal A; Flowers C; Fowler N; Wang L; Wang ML
Blood Adv; 2020 Mar; 4(6):1038-1050. PubMed ID: 32191807
[TBL] [Abstract][Full Text] [Related]
16. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
Beitinjaneh A; Kaufman A; Wang Y; Jain P; Srour SA; Wang M
Curr Treat Options Oncol; 2022 Nov; 23(11):1614-1625. PubMed ID: 36227407
[TBL] [Abstract][Full Text] [Related]
17. Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma.
Izban KF; Alkan S; Singleton TP; Hsi ED
Arch Pathol Lab Med; 2000 Oct; 124(10):1457-62. PubMed ID: 11035575
[TBL] [Abstract][Full Text] [Related]
18. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Wang M; Munoz J; Goy A; Locke FL; Jacobson CA; Hill BT; Timmerman JM; Holmes H; Jaglowski S; Flinn IW; McSweeney PA; Miklos DB; Pagel JM; Kersten MJ; Milpied N; Fung H; Topp MS; Houot R; Beitinjaneh A; Peng W; Zheng L; Rossi JM; Jain RK; Rao AV; Reagan PM
N Engl J Med; 2020 Apr; 382(14):1331-1342. PubMed ID: 32242358
[TBL] [Abstract][Full Text] [Related]
19. Smoldering mantle cell lymphoma.
Ye H; Desai A; Zeng D; Nomie K; Romaguera J; Ahmed M; Wang ML
J Exp Clin Cancer Res; 2017 Dec; 36(1):185. PubMed ID: 29246179
[TBL] [Abstract][Full Text] [Related]
20. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy.
Jain P; Nastoupil L; Westin J; Lee HJ; Navsaria L; Steiner RE; Ahmed S; Moghrabi O; Oriabure O; Chen W; Badillo M; Flowers CR; Wang ML
Br J Haematol; 2021 Jan; 192(2):e38-e42. PubMed ID: 33152104
[No Abstract] [Full Text] [Related]
[Next] [New Search]